Poly Medicure Ratios

Poly Medicure Ltd Ratios

The Poly Medicure Ltd Ratios page provides a complete fundamental analysis of Poly Medicure Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Poly Medicure Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Poly Medicure Ltd (NSE: POLYMED, BSE: 531768) is currently trading at ₹1333.40, with a market capitalization of ₹130.32B. As a major player in the Health technology sector and Medical specialties industry, Poly Medicure Ltd remains a key stock for fundamental analysis using Poly Medicure Ltd Ratios.

Poly Medicure Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Poly Medicure Ltd P/E ratio currently stands at 65.72, making it one of the most tracked metrics in Poly Medicure Ltd Ratios.

Historically, the Poly Medicure Ltd P/E ratio has shown strong fluctuations:

• 2024: 65.72
• 2023: 59.07
• 2022: 51.05
• 2021: 62.15
• 2020: 53.65

The rising Poly Medicure Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Poly Medicure Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 8.21.

Historical P/B trend:

• 2024: 8.21
• 2023: 10.37
• 2022: 7.36
• 2021: 8.37

Poly Medicure Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Poly Medicure Ltd P/S ratio currently stands at 13.43, an important part of Poly Medicure Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 13.43
• 2023: 11.15
• 2022: 8.24
• 2021: 9.91

The rising Poly Medicure Ltd P/S ratio indicates improved revenue valuation by investors.

Poly Medicure Ltd Price to Cash Flow Ratio (P/CF)

The Poly Medicure Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 91.10.

Historical Poly Medicure Ltd Price to Cash Flow Ratio:

• 2024: 91.10
• 2023: 56.76
• 2022: 49.54
• 2021: 73.69
• 2020: 64.18

The rising Poly Medicure Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Poly Medicure Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Poly Medicure Ltd EV currently stands at ₹212.24B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 212.24B
• 2023: 151.44B
• 2022: 89.99B
• 2021: 88.8B

Poly Medicure Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Poly Medicure Ltd EV/EBITDA ratio is currently 47.05, a key metric in Poly Medicure Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 47.05
• 2023: 41.99
• 2022: 33.15
• 2021: 41.28

Higher Poly Medicure Ltd EV/EBITDA suggests premium valuation.

Poly Medicure Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Poly Medicure Ltd D/E ratio is currently 0.07, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.07
• 2023: 0.12
• 2022: 0.12
• 2021: 0.12

Poly Medicure Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Poly Medicure Ltd ROE currently stands at 15.99%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 15.99
• 2023: 19.05
• 2022: 15.39
• 2021: 14.27

Poly Medicure Ltd maintains stable profitability levels.

Poly Medicure Ltd Ratios Analysis Summary

The Poly Medicure Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Poly Medicure Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Poly Medicure Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.